SLC7A3 and cancer: Our data presented in this report does not suggest that the arginine transporter CAT3 is a useful therapeutic target for controlling cancer cell access to arginine because Pten loss or an oncogenic Ptpn11 mutation-driven leukemia development is not impacted by Slc7a3 depletion.